Literature DB >> 6838817

Purification and characterization of dihydrofolate reductase from methotrexate-resistant human lymphoblastoid cells.

T J Delcamp, S S Susten, D T Blankenship, J H Freisheim.   

Abstract

Dihydrofolate reductase has been isolated from methotrexate-resistant WIL2 human lymphoblastoid cells. This subline produces ca. 150 times more enzyme than the parental drug-sensitive line. The reductase has been purified to homogeneity by methotrexate affinity chromatography, gel filtration, and preparative isoelectric focusing in a yield of 65%. The enzyme has a pI = 7.7 and a molecular weight of ca. 22000. The amino-terminal 27 amino acid residues have been determined, revealing the location of the single cysteine residue at position 6. Reaction of this cysteine with p-(hydroxy-mercuri)benzoate in the presence of reduced nicotinamide adenine dinucleotide phosphate (NADPH) results in a 5-fold increase in enzyme activity. Other agents including KCl, urea, and thiourea also cause enzyme activation. The Km values for NADPH and dihydrofolate are 0.25 and 0.036 microM, respectively. Mercurial activation of the enzyme results in a 27-fold increase in the Km for NADPH and a 35-fold increase in the Km for dihydrofolate.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6838817     DOI: 10.1021/bi00272a017

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  4 in total

1.  Identification of critical amino acid residues on human dihydrofolate reductase protein that mediate RNA recognition.

Authors:  Ningwen Tai; Yuyan Ding; John C Schmitz; Edward Chu
Journal:  Nucleic Acids Res       Date:  2002-10-15       Impact factor: 16.971

2.  Isolation of rat dihydrofolate reductase gene and characterization of recombinant enzyme.

Authors:  Y Wang; J A Bruenn; S F Queener; V Cody
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

3.  Antimycobacterial activities of 2,4-diamino-5-deazapteridine derivatives and effects on mycobacterial dihydrofolate reductase.

Authors:  W J Suling; L E Seitz; V Pathak; L Westbrook; E W Barrow; S Zywno-Van-Ginkel; R C Reynolds; J R Piper; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.

Authors:  E Izbicka; A Diaz; R Streeper; M Wick; D Campos; R Steffen; M Saunders
Journal:  Cancer Chemother Pharmacol       Date:  2009-02-17       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.